By the year 2023, Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market is expected to reach USD 16.09 Billion at CAGR of 9.00%. Market Overview: In the year 2018, Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market was valued at USD 10.46 Billion. By the year 2023, it is predicted to reach USD 16.09 Billion with pace of 9.00% CAGR. Among children and adults Attention deficit hyperactivity disorder (ADHD) is a psychiatric/neurological disorder. It is common in children below 12 years when compared to adults. ADHD is also known as neuropsychiatric disorder or hyperkinetic disorder/ attention deficit disorder. There is no concrete evidence with respect to the exact cause of ADHD disorder. But it is said to be caused by genetic factors and environmental influences. Symptoms of the disease include lack of concentration, impatience, distraction and difficulty in remembering things. ADHD can be controlled by medication, education/training and psychotherapy. Request Report Sample: https://www.marketdataforecast.com/market-reports/attentiondeficit-hyperactivity-disorder-therapeutics-market-304/request-sample Increasing awareness about mental illness and advancements in the medical field Factors affecting market growth: • Increasing awareness among people about psychological disorders. (+) • Increasing advancements in medical field. (+) • Concentration of biotechnology and pharmaceutical companies to develop effective therapeutics. (+) • Expensive prices of ADHD medications. (-) • Side effects such as insomnia, dizziness, headaches and mood swings. Get your customized report: https://www.marketdataforecast.com/marketreports/attention-deficit-hyperactivity-disorder-therapeutics-market-304/customize-report North America holds the major share of Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market. Market Segmentation Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market is geographically segmented into • North America. • Europe. • Asia Pacific. • Latin America. • Middle East and Africa. North America topped the list with 36% of Attention Deficit Hyperactivity Disorder market in 2018. In addition, Asia Pacific region is estimated grow faster at highest CAGR of 12.30% during forecasted period of 2018-2023. The market is expected to grow due to increased disposable incomes and presence of economically evolving regions. Browse full Table of Contents: https://www.marketdataforecast.com/marketreports/attention-deficit-hyperactivity-disorder-therapeutics-market-304/ Key players: Key players competing in the Global Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market include Curemark, LLC. (U.S.), Johnson & Johnson (U.S.), Novartis AG (Switzerland), Noven Pharmaceuticals, Inc. (U.S.), Supernus Pharmaceuticals, Inc. (U.S.), Alcobra Ltd. (Israel), Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), Neos Therapeutics, Inc. (U.S.), and Shire plc (Ireland). Contact Info: Name: Mr. Abhishek Shukla Email: [email protected] Organization: MarketDataForecast™ Address: 2nd Floor, Above ICICI Bank,B-44, Rd Number 3, Journalist Colony, Film Nagar, Hyderabad, Telangana 500033, India. Phone: +1-888-702-9626

Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (<12 years age) as compared to adolescents.